Briacell Therap (NASDAQ:BCTX) Shares Down 0.5% – Time to Sell?

Briacell Therap (NASDAQ:BCTX) shares traded down 0.5% during trading on Wednesday. The company traded as low as $3.91 and last traded at $4.00. 84,437 shares were traded during trading, a decline of 42% from the average daily volume of 145,678 shares. The stock had previously closed at $4.02.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Briacell Therap Stock Down 0.3%

The stock has a market cap of $34.02 million, a price-to-earnings ratio of -0.49 and a beta of 1.21. The stock’s fifty day moving average is $3.76 and its 200-day moving average is $3.71.

About Briacell Therap

BriaCell Therapeutics Corp. (NASDAQ: BCTX) is a clinical-stage biotechnology company developing targeted immunotherapies for cancer. The company focuses primarily on treatments for advanced breast cancer, with an emphasis on stimulating a patient’s immune system to recognize and attack tumor cells.

BriaCell’s lead product candidate is Bria-IMT, an immunotherapy derived from a breast cancer cell line and designed to activate cancer-fighting immune responses. The company has evaluated Bria-IMT in clinical studies for metastatic breast cancer, including in combination with immune checkpoint inhibitors.